Library

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2019, T. 119, No. 9

Summary:
Purpose of the study. Studying the effectiveness and safety of therapy with a medicine (LP) Mexidol, used intravenously (500 mg 1 time per day) in the form of infusions for 14 days, followed by orally orally Mexidol Fort 250 in a dose of 250 mg (1 tablet) 3 times a The day for 60 days in patients with chronic ischemia of the brain against the background of arterial hypertension and atherosclerosis. Material and methods. The open observation program includes 60 patients with an established diagnosis of chronic brain ischemia, confirmed by neuroimaging research methods. Results and conclusion. The results of the study showed high efficiency and safety of sequential therapy (injections and then taking the tablet form of the LP Mexol Forte 250). Against the background of treatment, an improvement in emotional and cognitive status, a decrease in motor disorders, as well as the severity of subjective manifestations are noted. High commitment to patients to the therapy is shown. Keywords: chronic brain ischemia, arterial hypertension, atherosclerosis, ethylmethylhydroxypyrididine succinate, mexidol, cognitive disorders.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2019, T. 119, No. 8

Summary:
one of the leading causes of mortality, disability and pronounced maladaptation of patients is an ischemic stroke, which accounts for about 80% of all types of acute cerebrovascular accident. At the same time, approximately 2/3 of patients detect residual phenomena of cerebrovascular circulation disorders of varying degrees of severity. Currently, the problem of ischemic stroke is given great attention, and one of the aspects of work in this area is the developed international and domestic recommendations for the prevention of stroke, treatment and rehabilitation of patients who have undergone stroke. The article provides an overview of the latest clinical recommendations for the early management of patients with acute ischemic stroke of the American Association on the Problems of the Heart and the American Association for the Treatment of Stroke, as well as the features of the therapy and prevention of stroke in Russia, European and the USA. Key words: ischemic stroke, clinical recommendations, therapy of ischemic stroke.

Place of publication:
Bulletin of Otorinolaryngology, 2019, T. 84, No. 6

Summary:
with vascular etiology of neurosenate hearing loss, hearing changes can occur as a result of the vertebral-baslar failure of various etiologies. Features of the etiology and pathogenesis of chronic neurosenate hearing loss allow us to consider very promising the use of neuroprotective drugs in the therapeutic complex that can activate the structure and function of neuronal structures of the analyzer trace. Ethylmethylhydroxypirinidine of succinate, possessing comprehensive pharmacological capabilities and a wide spectrum of effects realized at neuronal and vascular levels can be used in the therapy of hearing impairment and intelligibility of speech. Keywords: hearing loss, neurosenate hearing loss, rehabilitation of the auditory function, ethylmethylhydroxypyridine succinate.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova Stroke No. 4/2019

Summary:
the review presents data on the combined use of Mexidol in combination with drugs of various pharmacotherapeutic groups. Possessing the multimodal action mechanism and a wide range of pharmacological effects, Mexoling enhances the main effect of drugs both in the experiment and in the clinic, increases the effectiveness of therapy prescribed by patients in accordance with current federal standards, and also helps to reduce the severity of complications of diseases. The data on the efficiency and pathogenetic validity of the course combination therapy with other preparations presented in the review indicate the advisability of this approach for the treatment of cerebrovascular and cardiovascular diseases, diseases of the nervous system, open-angle glaucoma, alcohol intoxication and a number of other diseases. Key words: Mexidol, combined therapy, free radicals, lipid oxidation, ischemic stroke, myocardial infarction, coronary heart disease, epilepsy, glaucoma, alcohol intoxication.

Place of publication:
special release of the journal of neurology and psychiatry named after S.S. Korsakov Stroke No. 3.2/2019

Summary:
Purpose of the study. To study in dynamics the rheological properties of blood in patients with acute ischemic stroke (AI) when Mexidol is included in complex therapy. Material and methods. 60 patients with acute AI examined. Mexidol (500 mg/day intravenously within 20 days) received 32 patients, 28 patients received magnesium sulfate (2000 mg/day intravenously for 20 days). The control group included 20 patients without a history of cardiovascular pathology. Assessment of rheological indicators of blood (whole blood viscosity, plasma viscosity, hematocrit, aggregation and deformability of red blood cells, the level of fibrinogen in plasma) was carried out in patients three times: during the first 12 hours, on the 3-5th day and on the 18-20th day and on the 18th-20th day After hospitalization. Results. All patients with a stroke observed a high viscosity syndrome. A statistically significant decrease in blood viscosity was detected in patients receiving Mexidol, by the 3-5th day of the disease at low shift speeds and by the 18-20 days at the speed of the shift from 3-100 S1. By the 18-20th day of the disease, reliable differences in the value of hematocrit (p = 0.026) and the content of fibrinogen (p = 0.017) were revealed in groups of patients receiving various therapy. A reliable increase in the erythrocyte deformability index in patients who received the therapy with Mexidol by the 3-5th day at the shift speeds of 90 and 890 S-1, by the 18-20th day at the shift speeds 90–360 S-1, was recorded. Conclusion. The study shows the effect of Mexol's drug on blood fluidity in the dynamics of acute cerebral ischemia and its effectiveness is proved in reducing blood viscosity by reducing the level of hematocrit and fibrinogen, as well as an improvement in the deformation ability of red blood cells. Keywords: acute ischemic stroke, rheological indicators of blood, blood viscosity, erythrocyte deformability, Mexidol (2-ethyl-6-methyl-3-hydroxypirinate), treatment of brain ischemia.

Place of publication:
New therapeutic journal "Non Nocera" No. 11, 2018

Summary:
cognitive violations of varying degrees are laid by severe economic and emotional burden on the families of patients and society as a whole. Modern methods of therapy in most cases reduce the severity of violations and increase the duration of an active independent life.

Place of publication:
“Neurology, neuropsychiatry, psychosomatics”, 2018; 10 (3): 86–90

Resume:
The purpose of the study is to assess the influence of intravenous administration of Mexidol during the “therapeutic window” on the effectiveness of intravenous thrombolytic therapy (TLT). Patients and methods. A retrospective study includes 123 patients with an ischemic stroke (AI) who conducted intravenous TLT in the conditions of the vascular centers of the Republic of Tatarstan. To assess the dynamics of neurological status, they used the scale of the severity of the National Institute of Health (National Stroke Scale (Nihss). Depending on the initial severity of the neurological deficiency, all patients were divided into three subgroups: with mild severity (Lee) and an assessment by NIHSS at admission <8 points; with moderate severity (si) - with an assessment> 8 and <16 points; With heavy AI (TI) - with an assessment> 16 points. X -ray computed tomography was performed by all patients at the time of admission, 24 hours after the TLT, as well as with a deterioration in the condition. Results. The use of Mexidol at the prehospital stage, followed by TLT in patients with AI positively affects the regression of neurological deficiency, regardless of the severity of the disease. Reliable differences in the degree of regression of the neurological deficiency according to NIHSS 24 hours and 10 days after receipt of patients with TI who were introduced by Mexidol at the prehospital stage were revealed and who did not receive this drug before the implementation of TLT. The use of Mexidol before TLT promotes greater regression of neurological deficiency. A lower frequency of development of hemorrhagic transformations has been established in patients who received Mexidol at the prehospital stage, in comparison with patients who did not use this drug. Conclusion. The data obtained demonstrate the positive effect of Mexidol on the effectiveness and safety of TLT in patients with AI. Keywords: ethylmethylhydroxypyridine succinate; intravenous thrombolytic therapy; ischemic stroke; Neuroprotective therapy.

Place of publication:
neurology, neuropsychiatry, psychosomatics. 2018, No. 10

Summary:
The purpose of the study is to assess the effectiveness of the inclusion of Mexidol in complex drug therapy in patients in the acute period of ischemic (AI) and hemorrhagic stroke. Patients and methods. 60 patients aged 60–74 years with a first -aimed stroke were examined: 34 of them were diagnosed with AI, in 26 - intra -core hemorrhage (Navy). The main group was 31 patients who received, in addition to therapy in accordance with the standards adopted in the Russian Federation, Mexidol. The comparison group included 29 patients who were prescribed only standard therapy. Before and against the background of intravenous drip administration of Mexidol, 500 mg for 10 days, indicators were assessed by the stroke scale of the American National Institute of Health (National Institutes of Health Stroke Scale, NiHSS), the Rivermide mobility index and the Rankin scale and the Bartel index. The percentage absorption of lipid phospholipid complexes in the infrared spectrum of blood serum was also investigated. The control group amounted to 20 practically healthy persons. Results and discussion. It was found that the dynamics of lipid phospholipid complexes of the blood serum correlate with the type of stroke. The inclusion of Mexidol in complex drug therapy in elderly patients in the acute period of AI and Navy contributed to the regression of focal neurological deficiency, improving daily activity and functional independence. Mexidol's reception had a positive effect on the level of phospholipids of neuronal membranes. Conclusion. Mexidol’s positive effect on the level of blood serum phospholipids was noted. The conclusion was made about the effectiveness of its inclusion in the complex therapy of the acute period of AI and hemorrhagic stroke, especially in the elderly. Key words: ischemic stroke; intracassium hemorrhage; therapy; Mexidol; phospholipids.

Place of publication:
“Journal of Neurology and Psychiatry”, 10, 2018

Summary:
antihypoxic, antioxidant and nootropic effects of Mexidol contribute to improving the condition of patients with cerebrovascular pathology. The results of clinical studies show that the sequential scheme for the use of the drug (first intravenously or intramuscularly, then orally) is effective in the complex therapy of ischemic diseases of the brain, vascular surgery, therapy and rehabilitation of patients with degenerative-dystrophic changes in the spine, with neurodegenerative pathology, infectious neuropathies, a and Also in therapy of neuropsychological and autonomic disorders.

Place of publication:
a journal of neurology and psychiatry, 9, 2018; Ext. 2

Summary:
Purpose of the study. To study the clinical efficiency, metabolic and membraneproprothetic effects of Mexidol with transient ischemic attacks (TIA) in the vertebral-baslar system (VBS) in elderly patients with chronic brain ischemia (HIGM). Material and methods. 53 patients aged 60 to 74 years with the first episode of TIA in the WBS against the background of HIGM were examined. The main group included 33 patients who received Mexidol in addition to standard therapy (500 mg for 10 days). The comparison group consisted of 20 patients who received only standard therapy. They studied the dynamics of clinical manifestations of TIA, indicators of the state of oxidant and antioxidant systems, as well as the percentage absorption of lipid phospholipid blood serum complexes in the infrared spectrum. The control group amounted to 20 practically healthy patients. Results and conclusion. The use of Mexidol is associated with faster regression of focal neurological deficiency. The drug reliably reduced the intensity of lipid peroxidation and had a positive effect on the level of phospholipids of neuronal membranes. The identified metabolic and membraneproprothetic effects of Mexidol, as well as the positive effect of the drug on the regression of the focal neurological deficiency substantiate its inclusion in the complex therapy of the TIA in the WBS against the background of HIGM, especially in elderly patients. Key words: transient ischemic attack, vertebral-baslar system, chronic brain ischemia, mexidol, lipid oxidation, phospholipids.

Place of publication:
Journal of Neurology and Psychiatry, 8, 2018

Summary:
Purpose of the study. Assess the effect of mono- and combined therapy with Mexidol with young patients with cerebral angiodistonia. Material and methods. 90 patients (38 men and 52 women aged 25 to 44 years) were examined with vegetative dysfunction syndrome in the form of asthenovegetative and cephalgic syndromes taking Mexidol (1st group, 30 patients), Vinpocetin (2nd group, 30) and 30) and 30) and 30) and 30) and 30) Their combination (3rd group, 30). The condition of cerebral hemodynamics was evaluated using an algorithm for complex ultrasound examination, the state of autonomic regulation - by analyzing the variability of the heart rhythm, the functional state of microcirculation - by conducting a laser Doppler flower before and 10 days after the course of use of drugs. Results and conclusion. Mexidol in both mono and complex treatment of patients with cerebral angiodistonia possessed a vegetostabilizing, cerebrooprotective effect. An improvement in cerebral hemodynamics and microhemocirculation was revealed. As part of combined therapy (Mexidol and Vinpocetin), the effect of each drug was enhanced, and the adaptation of cerebral blood flow took place much faster than when using only winepocetine. Thus, the use of combined therapy (Mexidol and Vinpocetin) in patients with cerebrovascular pathology helps to minimize the negative prognosis of the development of the disease and may impede the development of acute cerebrovascular disorders. Keywords: Mexidol, Vinpocetin, microcirculatory disorders, autonomic dystonia, laser Doppler floometry, Cerebral angiodistonia.

Place of publication:
Journal of Neurology and Psychiatry, 4, 2018

Summary:
Purpose of the study. Assessment of the effectiveness and tolerance of the drug Mexidol as a corrector of cognitive disorders in patients with arterial hypertension and clinical manifestations of chronic cerebrovascular accident. Material and methods. 42 patients with clinical manifestations of chronic brain ischemia (chemical) and cognitive disorders were examined. Patients of the 1st group (n = 21) received traditional antihypertensive therapy, patients of the 2nd group (n = 21)-antihypertensive drugs and Mexidol. To evaluate the neuropsychological status, MMSE, Mosa, Mosa, Watch Drawing West were used. To control the adherence to therapy, a survey was carried out using the Morisk -Grine test. Results and conclusion. After the course of treatment with Mexidol, the number of patients with a lack of complaints increased by 3 times, headache regression was noted in 90% of patients, improving memory, concentration of attention, and the disappearance of anxiety in 50, 55, 67%, respectively. In patients of the 2nd group (Mexidol), more significant changes have occurred for the watch drawing test compared to the 1st group (0.95 and 0.54 points, And Mosa, which indicates the effective effect of the drug on cognitive symptoms of neurodynamic type and well -being in patients with chemical genesis. The drug Mexidol is recommended for the use of patients in this group as part of the complex therapy of the underlying disease. Key words: Mexidol, cognitive impairment, commitment.

Place of publication:
Journal of Neurology and Psychiatry, 2, 2018

Summary:
Purpose of the study. Track the dynamics of biochemical markers of inflammation and indicators of damage to the brain tissue in the acute period of ischemic stroke (AI) in the background of taking submaximal doses of the drug Mexidol. Material and methods. The study included 60 patients received in the first 6 hours from the onset of the disease, with verified AI on the Aspects scale 7–9 points. Patients of the main group (n = 30) received submaximal doses of Mexidol - 750 mg of the drug diluted in 250.0 ml of physiological solution, 2 times a day intravenously for 6 days. Patients of the control group (n = 30) were prescribed standard therapy. All patients were determined by biomarkers, an assessment of the neurological status within 60 minutes from the moment of receipt to the hospital and on the 7th day. Results and conclusion. In both groups, the indicators of the C-reactive protein, Interleukin-6 and fibrinogen changed slightly and did not have reliable significance in assessing the effectiveness of Mexidol. The indicators of biomarkers such as brainwater peptide and pretein plasma-A protein-A, as well as the average indicators in the NIHSS and MFI-20 scales in a group of patients receiving Mexidol, have significantly decreased compared to the control group. The results indicate a decrease in oxidant stress and signs of inflammation in the acute period of AI against the background of submaximal doses of the drug Mexidol, a decrease in the severity of neurological deficiency, and an increase in physical activity of patients. Given the time of activation of the damaged antioxidant system of the body, the recommended period of drug support is 3 months. Key words: antioxidant stress, inflammation, acute period, ischemic stroke, Mexidol.

Place of publication:
journal neurology, neuropsychiatry, psychosomatics, 1, 2018

Summary:
in elderly patients, dizziness can be caused by various causes, the possibilities of drug therapy are limited, the most commonly used are the betagistine of digidloride. The purpose of the study is to study the effectiveness and safety of complex therapy with Mexidol ^® and betagistin in patients with dizziness according to the global evaluation of the effectiveness of treatment. Patients and methods. The study includes 89 elderly patients (average age - 73.7 years) with chronic cerebrovascular pathology and dizziness complaints. In all patients, neurological, otoneurological (orthostatic samples, with forced hyperventilation, dix - medalpike, tinetti, visual analogue of dizziness), somatic, cognitive and emotional status. Patients were randomized into two groups. The main group included patients who received a betagistin of 48 mg/day, Mexidol ^® 5.0 ml intravenously for 10 days, then 375 mg/day tablets; In the comparison group - patients who used only 48 mg/day betagistine for 60 days. Assessment of the effectiveness of treatment was carried out on a global scale on the 60th day of therapy in both groups, taking into account the opinion of the doctor and the patient. Results. In elderly patients, dizziness in most cases (75%) was caused by several causes. In a group of combined treatment (betagistin + Mexidol ^® ), a more significant (more than doubled) decrease in dizziness symptoms are noted than in the comparison group. Conclusion. In elderly patients with chronic cerebrovascular disease and dizziness, combined therapy with Mexidol ^® and betagistin with neuroprotective properties improves treatment results.

Place of publication:
a journal of neurology and psychiatry, 3, 2017; Ext. 2

Summary:
Purpose of the study. To evaluate the effectiveness and safety of prolonged sequential therapy with Mexidol with patients with hemispherical ischemic stroke (AI) in acute and early recovery periods. Material and methods. In a randomized double-centered placebo-controlled in parallel groups, the study included 151 patients (62 men and 89 women), 150 patients (62 men and 88 women) aged 40 to 79 years were randomized. Patients by simple randomization were distributed to 2 groups: patients of the 1st group received therapy with Mexidol of 500 mg/day intravenously for 10 days, followed by 1 tablet (125 mg) 3 times a day for 8 weeks. Patients of the 2nd group received a placebo according to a similar scheme. The duration of participation in the study was from 67 to 71 days. Results. At the time of the end of the therapy, the average score on the modified scale of Rankin (MSHR) was lower in the 1st group than in the 2nd (p = 0.04). The dynamics of reducing the average score according to MSHR (1-5th visit) was more pronounced in the 1st group (p = 0.023). The proportion of patients who have reached the recovery corresponding to 0-2 points in MSHR (5th visit) was significantly higher in the 1st group (p = 0.039). When testing on a stroke scale of the National Institute for Health to the 5th visit, the average value was lower in the 1st group (p = 0.035). A decrease in the score on the stroke scale of the National Institute for Health at the time of the end of the course of therapy regarding the initial level in patients with diabetes was more pronounced in the 1st group (p = 0.038). In the 1st group in the general population of patients and subpopulation of patients with diabetes, the dynamics of improving the quality of life was more pronounced and was observed from the 2nd visit. The proportion of patients with the lack of problems in space was significantly higher in the 1st group (p = 0.022). There were no reliable differences in the frequency of unwanted phenomena in patients of both groups. Conclusion. It is recommended that the use of Mexidol in the acute and early recovery periods of AI is recommended.

Place of publication:
Stroke, 18, 2006

Summary:
patients with an ischemic stroke at the age of 45–85 years (51 people) entered the first 24 hours from the onset of the disease were included in the study. Mexidol was introduced at a dose of 300 mg/day 24 patients for 14 days from the beginning of the stroke. The placebo was introduced by 27 patients according to a similar scheme. A reliable advanced dynamics in the regression of neurological disorders on the NIH scale by the 14th day of the disease in the group of patients who received Mexol compared to the placebo group (p <0.05), as well as a reliable functional restoration (the dynamics of the clinical score on the Bartel scale at 21, were identified. -y day; p <0.05) in patients included in the study in the first 6 hours of the disease. The normalization of the functional activity of the brain was established in the treatment of Mexidol, including during acute pharmacological test. The complex of studies of the antioxidant system revealed an increase in the activity of its enzymes (superoxidsmutase, glutathioneperoxidase, glutathioneuctase) with the introduction of Mexidol compared to placebo. When analyzing the enzymes of the respiratory chain of mitochondria, an increase in the activity of succinate dehydrogenase was noted. Thus, a reliable clinical confirmation of the effectiveness of Mexidol was obtained in the acute period of ischemic stroke in the carotid system of an atherotrombotic or cardiembolic pathogenetic type, especially with an early (up to 6 hours) its appointment; The mechanisms of action of the drug (antihypoxic, antioxidant) in clinical conditions are clarified.